Meeting Banner
Abstract #0369

1 H MRS detection of glutamate predicts survival in pediatric medulloblastoma

Martin Wilson 1,2 , Simrandip K Gill 1,2 , Lesley MacPherson 2 , Martin English 2 , Theodoros N Arvanitis 2,3 , and Andrew C Peet 1,2

1 School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom, 2 Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom, 3 Institute of Digital Healthcare, WMG, University of Warwick, Coventry, United Kingdom

Medulloblastoma is the most common malignant brain tumour occurring in childhood and the diversity of outcomes makes this a particularly challenging disease to treat. In this study, 1 H MRS was collected from 35 medulloblastoma patients and metabolite biomarkers were investigated to stratify high-risk patients. Glutamate was found to predict survival, and validated prospectively. 1 H HR-MAS was collected from a sub-set of patients and agreement between in-vivo and ex-vivo results was found, adding validation to the assignment of glutamate. The identification of glutamate as a predictive biomarker of survival in medulloblastoma provides a clinically viable measure and multi-center reproduction is warranted.

This abstract and the presentation materials are available to members only; a login is required.

Join Here